Familial colorectal cancer, beyond lynch syndrome

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 7, 2014, Pages 1059-1068

  Stoffel, Elena M ^a   Kastrinos, Fay ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Colorectal cancer; Genetic counseling; Genetic testing; Lynch syndrome

Indexed keywords

ADENOMATOUS POLYP; ARTICLE; ATTENUATED ADENOMATOUS POLYPOSIS; CANCER RISK; EPIGENETICS; FAMILIAL COLON POLYPOSIS; GENE MUTATION; HAMARTOMATOUS POLYPOSIS; HEREDITARY COLORECTAL CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; POLYPOSIS; COLORECTAL NEOPLASMS; COUNSELING; FAMILY HEALTH; GENETIC DISEASES, INBORN; GENETIC SCREENING; GENETICS;

COLORECTAL NEOPLASMS; COUNSELING; FAMILY HEALTH; GENETIC DISEASES, INBORN; GENETIC TESTING; HUMANS;

EID: 84902544333     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.08.015     Document Type: Article

References (61)

1. Levin B., Lieberman D.A., McFarland B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008, 134:1570-1595.
2. Fuchs C.S., Giovannucci E.L., Colditz G.A., et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994, 331:1669-1674.
3. Hereditary colorectal cancer and genetic testing. Gastroenterology 2001, 121:195-197. American Gastroenterological Association medical position statement.
4. Hampel H., Frankel W.L., Martin E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. JClin Oncol 2008, 26:5783-5788.
5. Quehenberger F., Vasen H.F., van Houwelingen H.C. Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. JMed Genet 2005, 42:491-496.
6. Jenkins M.A., Baglietto L., Dowty J.G., et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol 2006, 4:489-498.
7. Stoffel E., Mukherjee B., Raymond V.M., et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009, 137:1621-1627.
8. Aarnio M., Sankila R., Pukkala E., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81:214-218.
9. Vasen H.F., Mecklin J.P., Khan P.M., et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34:424-425.
10. Jarvinen H.J., Aarnio M., Mustonen H., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000, 118:829-834.
11. Mecklin J.P., Aarnio M., Laara E., et al. Development of colorectal tumors in colonoscopic surveillance in lynch syndrome. Gastroenterology 2007, 133:1093-1098.
12. Vasen H.F., Abdirahman M., Brohet R., et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 2010, 138:2300-2306.
13. National Comprehensive Cancer Network. Colorectal Cancer Screening. NCCN Clinical Practice Guidelines in Oncology. available: Accessed March 2013. http://www.nccn.org.
14. Lindor N.M., Petersen G.M., Hadley D.W., et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006, 296:1507-1517.
15. Moreira L., Balaguer F., Lindor N., et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012, 308:1555-1565.
16. Ladabaum U., Wang G., Terdiman J., et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011, 155:69-79.
17. Kastrinos F., Steyerberg E.W., Mercado R., et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011, 140:73-81.
18. Chen S., Wang W., Lee S., et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 2006, 296:1479-1487.
19. Dinh T.A., Rosner B.I., Atwood J.C., et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) 2011, 4:9-22.
20. Sieber O.M., Lipton L., Crabtree M., et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003, 348:791-799.
21. Jo W.S., Bandipalliam P., Shannon K.M., et al. Correlation of polyp number and family history of colon cancer with germline MYH mutations. Clin Gastroenterol Hepatol 2005, 3:1022-1028.
22. Grover S., Kastrinos F., Steyerberg E.W., et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 2012, 308:485-492.
23. Balaguer F., Castellvi-Bel S., Castells A., et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol 2007, 5:379-387.
24. Theodoratou E., Campbell H., Tenesa A., et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 2010, 103:1875-1884.
25. Aretz S., Stienen D., Friedrichs N., et al. Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). Hum Mutat 2007, 28:985-992.
26. van Lier M.G., Wagner A., Mathus-Vliegen E.M., et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 2010, 105:1258-1264. author reply 1265.
27. Giardiello F.M., Trimbath J.D. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006, 4:408-415.
28. Howe J.R., Mitros F.A., Summers R.W. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998, 5:751-756.
29. Sweet K., Willis J., Zhou X.P., et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005, 294:2465-2473.
30. Heald B., Mester J., Rybicki L., et al. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology 2010, 139:1927-1933.
31. Lindor N.M., Rabe K., Petersen G.M., et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005, 293:1979-1985.
32. Lindor N.M. Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome. Surg Oncol Clin N Am 2009, 18:637-645.
33. Cicek M.S., Cunningham J.M., Fridley B.L., et al. Colorectal cancer linkage on chromosomes 4q21, 8q13, 12q24, and 15q22. PLoS One 2012, 7:e38175.
34. Gray-McGuire C., Guda K., Adrianto I., et al. Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22. Cancer Res 2010, 70:5409-5418.
35. Pavicic W., Joensuu E.I., Nieminen T., et al. LINE-1 hypomethylation in familial and sporadic cancer. J Mol Med (Berl) 2012, 90:827-835.
36. Goel A., Xicola R.M., Nguyen T.P., et al. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 2010, 138:1854-1862.
37. Hitchins M.P., Wong J.J., Suthers G., et al. Inheritance of a cancer-associated MLH1 germ-line epimutation. N Engl J Med 2007, 356:697-705.
38. Suter C.M., Martin D.I., Ward R.L. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 2004, 36:497-501.
39. Ogino S., Nishihara R., Lochhead P., et al. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst 2013, 105:130-140.
40. Antelo M., Balaguer F., Shia J., et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One 2012, 7:e45357.
41. Lash R.H., Genta R.M., Schuler C.M. Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. J Clin Pathol 2010, 63:681-686.
42. Leggett B., Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010, 138:2088-2100.
43. Snover D.C. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011, 42:1-10.
44. Boparai K.S., Mathus-Vliegen E.M., Koornstra J.J., et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut 2010, 59:1094-1100.
45. Rex D.K., Ahnen D.J., Baron J.A., et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol 2012, 107:1315-1329.
46. Snover D.C., Ahnen D., Burt R., et al. Serrated polyps of the colon and rectum and serrated polyposis. WHO classification of tumours of the digestive system 2010, 160-165. IARC, Lyon, France. 4th ed. F.T. Bosman, F. Carneiro, R. Hruban (Eds.).
47. Kalady M.F., Jarrar A., Leach B., et al. Defining phenotypes and cancer risk in hyperplastic polyposis syndrome. Dis Colon Rectum 2011, 54:164-170.
48. Win A.K., Walters R.J., Buchanan D.D., et al. Cancer risks for relatives of patients with serrated polyposis. Am J Gastroenterol 2012, 107:770-778.
49. Boparai K.S., Reitsma J.B., Lemmens V., et al. Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. Gut 2010, 59:1222-1225.
50. Boparai K.S., Dekker E., Van Eeden S., et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 2008, 135:2014-2018.
51. Rashid A., Houlihan P.S., Booker S., et al. Phenotypic and molecular characteristics of hyperplastic polyposis. Gastroenterology 2000, 119:323-332.
52. Roberts A., Nancarrow D., Clendenning M., et al. Linkage to chromosome 2q32.2-q33.3 in familial serrated neoplasia (Jass syndrome). Fam Cancer 2011, 10:245-254.
53. Tenesa A., Dunlop M.G. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 2009, 10:353-358.
54. Goel A., Boland C.R. Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol 2010, 26:47-52.
55. Jasperson K.W., Tuohy T.M., Neklason D.W., et al. Hereditary and familial colon cancer. Gastroenterology 2010, 138:2044-2058.
56. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. Cancer Genome Atlas Network.
57. Domchek S.M., Bradbury A., Garber J.E., et al. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?. J Clin Oncol 2013, 31:1267-1270.
58. Robson M.E., Storm C.D., Weitzel J., et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010, 28:893-901.
59. Genetic testing for colon cancer: joint statement of the American College of Medical Genetics and American Society of Human Genetics. Genet Med 2000, 2:362-366. Joint Test and Technology Transfer Committee Working Group.
60. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96:261-268.
61. Kastrinos F., Allen J.I., Stockwell D.H., et al. Development and validation of a colon cancer risk assessment tool for patients undergoing colonoscopy. Am J Gastroenterol 2009, 104:1508-1518.